Medcolcanna Organics Announces Issuance of Shares Pursuant to Payment of Debenture Interest

Bogotá, Colombia--(Newsfile Corp. - January 17, 2022) - Medcolcanna Organics Inc. (CSE: MCCN) ("Medcolcanna", "MCCN" or the "Company"), a leading Colombian and globally integrated cannabis company, announces that it is issuing a total of 1,595,554 common shares in the capital of the Company ("Common Shares") to the holders of the secured convertible debentures of the Company (the "Debentures") that were issued during fiscal 2020. Pursuant to the terms of the Debentures, interest can be paid either in cash or Common Shares, at the discretion of the Company. In order to conserve cash, the Company has elected to pay the interest owing for the period from July 1, 2021 to December 31, 2021 in Common Shares. The Common Shares are being issued at a price of \$0.055 per share, such price being based on the sixty day volume weighted average trading price of the Common Shares on the facilities of the NEO Exchange Inc. up to December 29, 2021 when the Common Shares were delisted from that exchange and for December 30 and 31, 2021 on the facilities of the Canadian Securities Exchange ("CSE"), the exchange on which the Common Shares are currently listed. The issuance of the Common Shares allows the Company to settle certain debt owing to various creditors and preserve its working capital for growing the business as it works towards achieving self-sufficiency and being self-financing. Finalization of the issuance of the Common Shares set forth above is subject to the approval of the CSE.

Certain of the issuances described above are considered to be a "related party transactions" pursuant to Multilateral Instrument 61-101 as several of the creditors and recipients of Common Shares are related parties to the Company, but the Company is availing itself of the exemptions from obtaining a formal valuation and obtaining "majority of the minority" approval due to the exemptions available in Sections 5.5(a) and 5.7(1)(a) of said instrument.

ABOUT MEDCOLCANNA

Medcolcanna is a Canadian integrated medical cannabis company, whose fully licensed operations are based in Colombia. Led by a proven and successful management team, Medcolcanna has facilities in optimal growing locations which positions the Company to become a global leader in the medical cannabis market.

Medcolcanna employs state of the art organic agricultural technology and innovative pharmaceutical processes to produce high-quality products. The Company's scalable production model and network of pharmaceutical partnerships globally ensures that they remain at the forefront of the medical cannabis industry.

If you would like to receive News Releases via email as soon as they are published, please subscribe here: https://medcolcanna.com/contact-us/(https://www.newsfilecorp.com/redirect/q3x3vcoeoY) or write to info@medcolcanna.com (mailto:info@medcolcanna.com).

Additional information about Medcolcanna can be found on its web site at www.medcolcanna.com (https://www.newsfilecorp.com/redirect/nvqv3TPqPK)

Medcolcanna Investor Relations Contact:

Chris Reid, CFO Carrera 49b # 93-62 Bogotá, Colombia Phone: +571 642-9113

Email: info@medcolcanna.com (mailto:info@medcolcanna.com)

Forward-Looking Statements

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forwardlooking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to general business, economic, competitive, political and social uncertainties; and the delay or failure to receive board, shareholder or regulatory approvals for any proposed transaction, including those discussed herein. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release.

Medcolcanna assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.



To view the source version of this press release, please visit https://www.newsfilecorp.com/release/110430 (https://www.newsfilecorp.com/redirect/KJQJaIXGXm)